Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is 2.82 as of 2026-10-06T17:20:44.293Z.
Calculation as of: 2026-10-06T17:20:44.293Z.
Quote observation: 2026-10-06T17:20:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d465a3cb364884174ea279f6e96e1b331d3038a7942601b23d7c9becb19c45da
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
2.82
SECTOR MEDIAN · HEALTHCARE
2.39
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
+17.99%
vs the sector median at left
Market Cap
$1.13B
PB Ratio
1.47
TTM Avg
1.39
3Y Avg
2.53
5Y Avg
2.96
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.12B | 2.82 | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 74.09 | 45.91 | 26.58 | 47.52 |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.12B | 8.60 | 9.42 | 8.40 | 9.33 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 1.47 | 1.39 | 2.53 | 2.96 |
| OPKO Health, Inc. (OPK)vs › | $1.11B | 0.94 | 0.82 | 0.76 | 0.85 |
| STAAR Surgical Company (STAA)vs › | $1.11B | 3.04 | 3.45 | 3.71 | 7.12 |
| Nektar Therapeutics (NKTR)vs › | $1.14B | 1.27 | 7.66 | 5.46 | 3.76 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.14B | 1.77 | 1.60 | 2.65 | 4.16 |
| Replimune Group, Inc. (REPL)vs › | $1.09B | 10.30 | 4.68 | 2.66 | 2.59 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | 2.32 | 2.68 | 2.12 | 2.12 |
P/B Ratio
2.82
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
